Unit:
Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και ΈρευναLibrary of the School of Health Sciences
Author:
Bikou Konstantina
Supervisors info:
Βασίλειος Κουλουλίας, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Πέτρος Μπακάκος, Kαθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Ταυτόχρονη έναντι διαδοχικής χημειοακτινοθεραπείας σε ασθενείς με τοπικά προχωρημένο καρκίνο πνεύμονα. Αποτελεσματικότητα και ασφάλεια
Translated title:
Concurrent versus sequential chemoradiotherapy in patients with locally advanced lung cancer. Efficacy and safety
Summary:
Lung cancer is the second most commonly diagnosed cancer in both men and women but is the leading cause of cancer death worldwide. Non Small Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all lung cancer diagnoses while 35% of patients present with locally advanced disease (stage III) at diagnosis. This stage is the most controversial regarding therapeutic approach, since many different treatments are available, even if we exclude potentially surgical excisions.
Purpose of the review is to compare concurrent versus sequential chemoradiotherapy regarding effectiveness and safety of patients with locally advanced Non-Small Cell Lung Cancer.
In this retrospective study, we investigated 59 patients’ files that had chemoradiotherapy (concurrent and sequential) for locally advanced Non-Small Cell Lung Cancer in two oncology centers from 01/2017 to 12/2018. We found available data for 30 patients regarding progression disease. 86,7% of these patients had progression disease, while 23,7% of them were dead in the first year and 55,9% in the second year of diagnosis. Regarding the side effects from the treatment, 51,9% of the participants presented with esophagitis grade II, 46,35% and 1,9% presented with esophagitis grade I and III, respectively. Neither data for overall survival and progression free survival nor data for side effects (safety) had any difference related to the applied treatment (concurrent or sequential chemoradiotherapy).
Remarkable observation was that response to chemoradiotherapy was related with patient s overall survival, patients with partial or complete response to the treatment had 68% less danger of death compared to the patients with stable disease (no response), regardless of the applied treatment (concurrent or sequential chemoradiotherapy). Patient’s age was related as well with overall survival, as the age increases, the risk of death decreases, regardless of the applied treatment (concurrent or sequential chemoradiotherapy).
Main subject category:
Health Sciences
Keywords:
Concurrent, Sequential, Chemoradiotherapy, Locally advanced lung cancer
Number of references:
110
File:
File access is restricted only to the intranet of UoA.
Konstantina Bikou MSc.pdf
2 MB
File access is restricted only to the intranet of UoA.
